NCT01930396View on ClinicalTrials.gov

Use of Tinzaparin for Anticoagulation in Hemodialysis

PHASE4CompletedINTERVENTIONAL

Enrollment

191

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions

Kidney Failure, Chronic

Interventions

DRUG

Tinzaparin

DRUG

Unfractionated Heparin

DRUG

Placebo (for Tinzaparin)

0.9% Normal Saline

DRUG

Placebo (for Unfractionated Heparin)

0.9% Normal Saline

Trial Locations (1)

L8N 4A6

St. Joseph's Healthcare Hamilton, Hamilton

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

McMaster University

OTHER

collaborator

LEO Pharma

INDUSTRY

lead

Christine Ribic

OTHER

NCT01930396 - Use of Tinzaparin for Anticoagulation in Hemodialysis | Biotech Hunter | Biotech Hunter